Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2023-11-28 Remuneration Information
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
2023年限制性股票激励计划激励对象名单
Remuneration Information Classification · 95% confidence The document is titled as a 2023 restricted stock incentive plan list of incentive recipients for a company. It details the allocation of restricted stock to various executives and core technical personnel, including quantities and proportions. There is no indication of financial statements, audit information, or regulatory certifications. The content focuses on stock incentive allocations to management and key personnel, which aligns with disclosures related to remuneration or incentive plans. Given the nature of the document as a list of stock incentive recipients and allocations, it fits best under Remuneration Information (DEF 14A), which covers compensation and incentive details for executives and directors. The document length is short and does not represent a full report or announcement of a report publication, so it is not RPA or RNS. Therefore, the classification is DEF 14A with high confidence.
2023-11-28 Chinese
关于公司董事会换届选举的公告
Board/Management Information Classification · 100% confidence The document is an announcement from 美康生物科技股份有限公司 regarding the election of a new board of directors. It details the nomination and qualifications of candidates for the fifth board, including independent and non-independent directors. The document references compliance with company law and stock exchange regulations, and it is dated November 29, 2023. There is no financial data, earnings information, or report publication mentioned. The content focuses exclusively on board changes and nominations, which fits the category of Board/Management Information (MANG). The document length is 4317 characters, which is consistent with a detailed announcement rather than a brief notice or report publication announcement.
2023-11-28 Chinese
独立董事工作制度（2023年11月）
Governance Information Classification · 95% confidence The document is titled as "美康生物科技股份有限公司 独立董事工作制度" which translates to "Independent Director Work System of Meikang Biotechnology Co., Ltd.". It details the rules, duties, nomination, election, rights, obligations, and protections of independent directors within the company. The content is about governance structure, board composition, director independence, and related governance practices. There is no financial data, no audit results, no earnings information, no voting results, no capital changes, no legal proceedings, no merger or acquisition details, and no report publication announcements. The document is a governance framework or internal rules document related to board and director governance. Therefore, it fits best under Governance Information (CGR). The document length is sufficient and it is not a brief announcement or certification, so it is not RNS or RPA. Hence, the classification is CGR with high confidence.
2023-11-28 Chinese
独立董事提名人声明-徐玲
Board/Management Information Classification · 100% confidence The document is a public statement from the board nominating an independent director candidate for the company's board. It details the qualifications, compliance with regulatory requirements, and independence criteria for the nominee. There is no financial data, no report or presentation, no voting results, no legal proceedings, and no mention of any financial period or earnings. This type of document is related to board/management information, specifically about board nominations and changes. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and focused solely on nomination, not a report or announcement of a report, so it is not RPA or RNS.
2023-11-28 Chinese
独立董事候选人声明-田云鹏
Board/Management Information Classification · 95% confidence The document is a formal declaration by an independent director candidate of a company, detailing compliance with legal and regulatory requirements for the position. It includes statements about qualifications, independence, and adherence to relevant laws and stock exchange rules. There is no financial data, no report or presentation content, and no announcement of voting results or management changes. This type of document is related to board or management information, specifically concerning the nomination or candidacy of a board member. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 3224 characters, which is consistent with a detailed declaration rather than a brief announcement or a full report.
2023-11-28 Chinese
公司章程(2023年11月）
Governance Information Classification · 100% confidence The document is titled '章程' which translates to 'Articles of Association' or 'Company Bylaws'. It contains detailed chapters and sections about the company's organizational structure, shareholder rights, board of directors, management, financial accounting, profit distribution, auditing, and procedures for shareholder meetings. It references Chinese company law and securities law, and includes detailed governance rules and procedures. There is no indication that this is an annual report, financial statement, earnings release, or any other financial disclosure. Instead, it is a governance document outlining the internal rules and structure of the company. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial and contains the full text of the governance rules, not just an announcement or summary, so it is not a report publication announcement or regulatory filing. Confidence is high due to the clear nature of the document as company bylaws.
2023-11-28 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.